Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study A. Berezne, B. Ranque, D. Valeyre, M. Brauner, Y. Allanore, D. Launay, J. E. Kahn, L. J. Couderc, C. Joel, E. Hachulla, A. Kahan, J. Cabane, L. Guillevin, L. Mouthon (Paris, Bobigny, Lille, Suresnes, Bordeaux, France)
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Session: Interstitial lung disease in systemic and vascular disorders Session type: Thematic Poster Session Number: 1885
Disease area: Interstitial lung diseases, Pulmonary vascular diseasesRating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Berezne, B. Ranque, D. Valeyre, M. Brauner, Y. Allanore, D. Launay, J. E. Kahn, L. J. Couderc, C. Joel, E. Hachulla, A. Kahan, J. Cabane, L. Guillevin, L. Mouthon (Paris, Bobigny, Lille, Suresnes, Bordeaux, France). Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicentered open-label study. Eur Respir J 2008; 32: Suppl. 52, 1885
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial) Source: Eur Respir J, 59 (2) 2102930; 10.1183/13993003.02930-2021 Year: 2022
Intravenous cyclophosphamide therapy for patients with interstitial pulmonary disease associated with collagen vascular disorders. A single-center experience Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008
A retrospective review to assess the effect of prednisolone and azathioprine on usual interstitial pneumonia disease progression Source: Eur Respir J 2006; 28: Suppl. 50, 826s Year: 2006
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020 Year: 2020
Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018
Efficacy and toxicity of azathioprine plus corticosteroids in 32 patients with chronic persistent sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004
Infliximab therapy in patients with chronic progressive sarcoidosis – a retrospective follow-up study Source: Annual Congress 2008 - Sarcoidosis: pathophysiology and severity Year: 2008
Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012
Efficacy and safety of sequential three-step empirical therapy for chronic cough: a multi-center clinical study Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial Source: Eur Respir J 2008; 31: 1189-1196 Year: 2008
Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009
A retrospective analysis of methotrexate therapy as a steroid sparing agent within a UK severe asthma clinic Source: Annual Congress 2012 - Different ways to phenotype asthma Year: 2012
High-dose inhaled corticosteroids and add-on therapy use in adults in the UK: an observational study of 22,027 patients Source: Annual Congress 2004 - Primary care: asthma Year: 2004
A 12-week combination of clarithromycin and prednisone for the treatment of cryptogenic and radiation-induced organising pneumonia Source: International Congress 2015 – New insights into IIPs Year: 2015
An observational study on effectiveness of azathioprine in treatment of interstitial lung disease secondary to connective tissue disease Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019
Efficacy of rituximab in patients with connective tissue disease associated interstitial lung disease: Preliminary results in safety and clinical response Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Prolonged sirolimus therapy in advanced pulmonary lymphangioleiomyomatosis; a multicenter French experience Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Comparative analysis of the efficacy of glucocorticosteroids and antimetabolite drugs in treatment of patients with pulmonary sarcoidosis Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019